An imbalanced microbiome can promote the development of tumors.
In a groundbreaking discovery, researchers have unveiled a surprising link between an unbalanced microbiome and the stimulation of tumour growth in the body. The intricate relationship between interleukin-17 (IL-17), a key immune factor that regulates the gut microbiome, and cancer progression has been unraveled, shedding light on why certain therapies targeting IL-17 have shown limited success in slowing down tumour growth.
Led by the renowned oncologist, Florencia McAllister from The University of Texas MD Anderson Cancer Center, the study delved into the critical role of gut bacteria in modulating immune responses and its impact on tumour development. Initially aiming to explore the potential of IL-17 inhibition as a cancer therapy, the research took an unexpected turn when experiments revealed that deleting the gene responsible for the IL-17 receptor led to accelerated tumour growth instead of regression.
The gut, a hub for IL-17 production, houses a diverse array of microorganisms that trigger the release of IL-17 by intestinal cells. This intricate interplay regulates immune responses and maintains microbial balance within the gut. However, disruption of this delicate equilibrium sets off a detrimental feedback loop, where the absence of normal IL-17 signalling results in the accumulation of specific microbes. Consequently, the body ramps up IL-17 production to combat these bacteria, inadvertently fueling aggressive tumour growth in various organs, including the pancreas and the brain.
The silver lining in this discovery comes in the form of antibiotics, which have been shown to break this harmful cycle by reducing the excess of microbes in rodents with deficient IL-17 signalling. By restoring microbial balance, the detrimental effects of unchecked IL-17 production can be mitigated, offering a potential avenue for novel treatment strategies. The future holds promise for clinical trials combining IL-17 inhibition with therapies that regulate the gut microbiome, presenting a holistic approach to combatting cancer and other diseases exacerbated by microbiome dysregulation.
McAllister's upcoming trial involving anti-IL-17 drugs in pancreatic cancer patients undergoing fecal microbiota transplantation underscores the potential of this research to revolutionize cancer treatment paradigms. By harnessing the intricate crosstalk between the immune system, gut microbiota, and tumour growth, a new dawn in precision medicine may be on the horizon, offering hope for more effective and tailored therapies in the fight against cancer.
Source: [Nature Research](https://www.nature.com/articles/d42473-023-00412-1)
Led by the renowned oncologist, Florencia McAllister from The University of Texas MD Anderson Cancer Center, the study delved into the critical role of gut bacteria in modulating immune responses and its impact on tumour development. Initially aiming to explore the potential of IL-17 inhibition as a cancer therapy, the research took an unexpected turn when experiments revealed that deleting the gene responsible for the IL-17 receptor led to accelerated tumour growth instead of regression.
The gut, a hub for IL-17 production, houses a diverse array of microorganisms that trigger the release of IL-17 by intestinal cells. This intricate interplay regulates immune responses and maintains microbial balance within the gut. However, disruption of this delicate equilibrium sets off a detrimental feedback loop, where the absence of normal IL-17 signalling results in the accumulation of specific microbes. Consequently, the body ramps up IL-17 production to combat these bacteria, inadvertently fueling aggressive tumour growth in various organs, including the pancreas and the brain.
The silver lining in this discovery comes in the form of antibiotics, which have been shown to break this harmful cycle by reducing the excess of microbes in rodents with deficient IL-17 signalling. By restoring microbial balance, the detrimental effects of unchecked IL-17 production can be mitigated, offering a potential avenue for novel treatment strategies. The future holds promise for clinical trials combining IL-17 inhibition with therapies that regulate the gut microbiome, presenting a holistic approach to combatting cancer and other diseases exacerbated by microbiome dysregulation.
McAllister's upcoming trial involving anti-IL-17 drugs in pancreatic cancer patients undergoing fecal microbiota transplantation underscores the potential of this research to revolutionize cancer treatment paradigms. By harnessing the intricate crosstalk between the immune system, gut microbiota, and tumour growth, a new dawn in precision medicine may be on the horizon, offering hope for more effective and tailored therapies in the fight against cancer.
Source: [Nature Research](https://www.nature.com/articles/d42473-023-00412-1)
Comments
Post a Comment